Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.
Press Releases
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
March 13, 2019
BASKING RIDGE, N.J. (March 13, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of […]
Read MoreCaladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
March 11, 2019
BASKING RIDGE, N.J. (March 11, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of […]
Read MoreCaladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes
February 13, 2019
BASKING RIDGE, N.J. (February 13, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting […]
Read MoreCaladrius Biosciences to Present at Upcoming February Conferences
February 5, 2019
BASKING RIDGE, N.J. (February 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms […]
Read MoreCaladrius Biosciences to Participate in Upcoming January Conferences
January 7, 2019
Caladrius Biosciences to Participate in Upcoming January Conferences BASKING RIDGE, N.J. (January 7, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage […]
Read MoreCaladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference
November 9, 2018
BASKING RIDGE, N.J. (November 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune […]
Read MoreCaladrius Biosciences Reports 2018 Third Quarter Financial Results
November 8, 2018
Development programs remain on track accompanied by continued strong fiscal management. Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 8, 2018) […]
Read MoreCaladrius Biosciences Appoints Cynthia Schwalm to Board of Directors
November 8, 2018
BASKING RIDGE, N.J. (November 8, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting […]
Read MoreCaladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
November 2, 2018
BASKING RIDGE, N.J. (November 2, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select […]
Read MoreCaladrius Biosciences to Participate in Upcoming October Conferences
October 17, 2018
Caladrius Biosciences to Participate in Upcoming October Conferences Company Receives “Buzz of BIO” Award at the 2018 BIO Investor Forum BASKING RIDGE, N.J. (September 27, 2018) […]
Read MoreCaladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30, 2018
BASKING RIDGE, N.J. (August 30, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune […]
Read MoreCaladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results
August 9, 2018
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 9, […]
Read MoreCaladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET
August 2, 2018
Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET BASKING RIDGE, N.J. (August 2, 2018) […]
Read MoreCaladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
June 19, 2018
BASKING RIDGE, N.J. (June 19, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select […]
Read MoreCaladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions
June 5, 2018
Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions Sale of non-core asset brings $2.5 million in non-dilutive funding BASKING RIDGE, […]
Read MoreCaladrius Biosciences Reports 2018 First Quarter Financial Results
May 10, 2018
Caladrius Biosciences Reports 2018 First Quarter Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (May 10, 2018) – Caladrius Biosciences, […]
Read MoreCaladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time
May 3, 2018
Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (May 3, […]
Read MoreCaladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
April 10, 2018
“We are very pleased to receive SAKIGAKE status for CLBS12 in Japan. As a designated medicine under the SAKIGAKE Designation system, CLBS12 will have prioritized consultation, a dedicated review system to support the development and review process, as well as reduced review time from the normal 12 to 6 months. This is great news not only in practical terms, but also because we believe that it reflects the recognition by MHLW and PMDA of the therapeutic potential of CLBS12 for the patient population in desperate need of therapeutic options,” Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius.
Read MoreCaladrius Biosciences to Participate at Upcoming April Conferences
April 9, 2018
BASKING RIDGE, N.J. (April 9, 2018) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune […]
Read MoreCaladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results
March 22, 2018
Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2018) […]
Read More